SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001178913-21-001670
Filing Date
2021-05-10
Accepted
2021-05-10 11:21:05
Documents
4
Group Members
ALON LAZARUSARKIN BIO VENTURE GPGP LTD.ARKIN BIO VENTURES 2 L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D zk2126011.htm SC 13D 100097
2 EXHIBIT 1 exhibit_1.htm EX-99 9989
3 EXHIBIT 3 exhibit_3.htm EX-99 46312
4 EXHIBIT 5 exhibit_5.htm EX-99 3836
  Complete submission text file 0001178913-21-001670.txt   161602
Mailing Address 6 HACHOSHLIM ST. HERZELIA L3 4672406
Business Address
Arkin Moshe (Filed by) CIK: 0001321178 (see all company filings)

Type: SC 13D

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-92515 | Film No.: 21905736
SIC: 2834 Pharmaceutical Preparations